Difference between revisions of "Part:BBa K4165195"
Line 7: | Line 7: | ||
===Usage and Biology=== | ===Usage and Biology=== | ||
− | + | Segments of amyloid beta fibrils are widely used as a recognition sequence for amyloid beta plaques inside the brain, this is due to the homotypic interactions in the C-terminus of fibrils. This peptide starts from amino acid 29 to 42 of the fibril. This binding peptide starts from amino acid 34 to 42. | |
===<span class='h3bb'>Sequence and Features</span>=== | ===<span class='h3bb'>Sequence and Features</span>=== | ||
<partinfo>BBa_K4165195 SequenceAndFeatures</partinfo> | <partinfo>BBa_K4165195 SequenceAndFeatures</partinfo> | ||
− | |||
− | |||
− | |||
− | |||
− | |||
===References=== | ===References=== |
Revision as of 19:53, 11 October 2022
Amyloid beta peptide 15 (Aβ 34-42)
This part encodes a part of the Amyloid 𝛽 fragment (34-42) which has the ability to bind to A𝛽 plaques inside the brain.
Usage and Biology
Segments of amyloid beta fibrils are widely used as a recognition sequence for amyloid beta plaques inside the brain, this is due to the homotypic interactions in the C-terminus of fibrils. This peptide starts from amino acid 29 to 42 of the fibril. This binding peptide starts from amino acid 34 to 42.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
References
1-Zhao, Y., Cai, J., Liu, Z., Li, Y., Zheng, C., Zheng, Y., ... & Liu, Y. (2018). Nanocomposites inhibit the formation, mitigate the neurotoxicity, and facilitate the removal of β-amyloid aggregates in Alzheimer’s disease mice. Nano letters, 19(2), 674-683.
Dry lab
Modeling
Due to the nonavailability of a model to this peptide we modeled it in our used modeling software's and after the Running of the quality assessment, the models have been scored to get the top model.
Figure 1.: Amyloid-beta (34-42) top model visualized by pymol.